Relay Therapeutics, Inc.
RLAY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $1 | $8 | $0 |
| % Growth | – | -91.2% | – | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | $1 | $8 | $0 |
| % Margin | – | 100% | 100% | – |
| R&D Expenses | $68 | $64 | $74 | $68 |
| G&A Expenses | $0 | $14 | $19 | $17 |
| SG&A Expenses | $11 | $14 | $19 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $80 | $78 | $93 | $85 |
| Operating Income | -$80 | -$77 | -$85 | -$85 |
| % Margin | – | -11,351.1% | -1,105.2% | – |
| Other Income/Exp. Net | $6 | $6 | $8 | $9 |
| Pre-Tax Income | -$74 | -$70 | -$77 | -$76 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | -$74 | -$70 | -$77 | -$76 |
| % Margin | – | -10,395.1% | -1,003.6% | – |
| EPS | -0.43 | -0.41 | -0.46 | -0.45 |
| % Growth | -4.9% | 10.9% | -2.2% | – |
| EPS Diluted | -0.43 | -0.41 | -0.46 | -0.45 |
| Weighted Avg Shares Out | 172 | 171 | 169 | 167 |
| Weighted Avg Shares Out Dil | 172 | 171 | 169 | 167 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $7 | $8 | $9 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$73 | -$76 | -$84 | -$84 |
| % Margin | – | -11,203.1% | -1,089.5% | – |